secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuphoria Therapeutics Inc. (NEUP)
CIK:        0001191070
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001213900-25-100371
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuphoria Phase 3 trial of BNC210 for social anxiety disorder fails primary endpoint; SAD program discontinued
--------------------------------------------------------------------------------

- AFFIRM-1 Phase 3 trial did not meet primary endpoint of change in SUDS scores during speech challenge; secondary endpoints also not significant.
- Company discontinues further development of SAD program; plans full strategic review of operations and portfolio by year-end.
- Cash and equivalents $14.2M as of June 30, 2025; expected to fund operations through Q2 fiscal 2027.
- Ongoing Merck partnership: MK-1167 in Phase 2 for Alzheimer's; Neuphoria eligible for up to $450M in milestone payments plus royalties.
- Given prior chronic dosing data, Neuphoria will evaluate next steps for BNC210 in PTSD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1191070/000121390025100371/0001213900-25-100371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1191070/000121390025100371/ea0261841-8k_neuphoria.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-100371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer